Apellis Pharmaceuticals Inc Cash Flow Conversion Efficiency
Apellis Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has a cash flow conversion efficiency ratio of -0.147x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-60.97 Million) by net assets ($414.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Apellis Pharmaceuticals Inc (2013–2025)
Cash flow conversion efficiency of Apellis Pharmaceuticals Inc from 2013 to 2025. This chart illustrates how Apellis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Apellis Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Apellis Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Apellis Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Apellis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market cap of Apellis Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fiducial Real Estate SA
PA:ORIA
|
0.047x |
|
Taiwan Navigation Co Ltd
TW:2617
|
0.033x |
|
Shenzhen Keanda Electronic Techno
SHE:002972
|
0.002x |
|
Nuveen Variable Rate Preferred & Income Fund
NYSE:NPFD
|
0.113x |
|
Shenzhen Jiang and Associates Creative Design Co Ltd
SHE:300668
|
0.019x |
|
Facc AG
VI:FACC
|
0.002x |
|
Burstone Group Limited
JSE:BTN
|
0.014x |
|
Meteoric Resources NL
AU:MEI
|
-2.091x |
Annual Cash Flow Conversion Efficiency for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Apellis Pharmaceuticals Inc from 2013 to 2025. Review Apellis Pharmaceuticals Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $370.15 Million | $45.33 Million | 0.122x | +131.85% |
| 2024-12-31 | $228.54 Million | $-87.87 Million | -0.384x | +87.43% |
| 2023-12-31 | $194.52 Million | $-594.74 Million | -3.057x | -1.10% |
| 2022-12-31 | $169.87 Million | $-513.75 Million | -3.024x | -6.69% |
| 2021-12-31 | $198.66 Million | $-563.13 Million | -2.835x | -261.30% |
| 2020-12-31 | $204.56 Million | $-160.49 Million | -0.785x | +87.28% |
| 2019-12-31 | $34.23 Million | $-211.13 Million | -6.168x | -656.56% |
| 2018-12-31 | $160.97 Million | $-131.24 Million | -0.815x | -160.61% |
| 2017-12-31 | $148.94 Million | $-46.60 Million | -0.313x | +71.37% |
| 2016-12-31 | $23.79 Million | $-26.00 Million | -1.093x | -102.71% |
| 2015-12-31 | $34.98 Million | $-18.86 Million | -0.539x | +28.33% |
| 2014-12-31 | $13.22 Million | $-9.95 Million | -0.752x | +1.25% |
| 2013-12-31 | $4.52 Million | $-3.44 Million | -0.762x | -- |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more